Lipid Efficacy and Safety in Participants With Mixed Hyperlipidemia (MK-0524B-024)

PHASE3CompletedINTERVENTIONAL

Enrollment

2,340

Participants

Timeline

Start Date

January 24, 2006

Primary Completion Date

August 6, 2010

Study Completion Date

August 6, 2010

Conditions

Mixed Hyperlipidemia

Interventions

DRUG

MK-0524A

DRUG

Atorvastatin

DRUG

Simvastatin

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00289900 - Lipid Efficacy and Safety in Participants With Mixed Hyperlipidemia (MK-0524B-024) | Biotech Hunter | Biotech Hunter